<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>PS1924: Zilovertamab Vedotin in R/R DLBCL (waveLINE-003)</title>
    
    <meta name="study:id" content="wavelLINE-003-ps1924">
    <meta name="study:title" content="PS1924: Zilovertamab Vedotin + R-GemOx in R/R DLBCL">
    <meta name="study:fileName" content="Abstracts/Armand_EHA2025_PS1924.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L, 3L+">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Zilovertamab Vedotin,ADC,Rituximab,Monoclonal Antibody,Chemotherapy">

    <script src="https://cdn.tailwindcss.com"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link rel="stylesheet" href="abstract_styles.css">
    <script src="../abstract_features.js" defer></script>
</head>

<body class="abstract-page-body">

    <div class="slide-container">

        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: ZV + R-GemOx in R/R DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg style="color: var(--sobi-dark-blue);" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor">
                        <path stroke-linecap="round" stroke-linejoin="round" d="M18 18.72a9.094 9.094 0 0 0 3.741-.479 3 3 0 0 0-4.682-2.72m-7.5-2.226A3 3 0 0 1 18 15.75a3 3 0 0 1-2.25 2.72m-7.5-2.226a3 3 0 0 0-2.25 2.72 3 3 0 0 0 4.682 2.72m-3.741-.479A9.094 9.094 0 0 1 12 18.75c-2.436 0-4.64-.932-6.259-2.44m12.518-5.318a3 3 0 0 1-2.25-2.72 3 3 0 0 1 2.25-2.72 3 3 0 0 1 2.25 2.72 3 3 0 0 1-2.25 2.72M12 11.25a3 3 0 0 1-2.25-2.72 3 3 0 0 1 2.25-2.72 3 3 0 0 1 2.25 2.72 3 3 0 0 1-2.25 2.72M12 11.25V18.75m0 0A9.094 9.094 0 0 1 12 18.75c-2.436 0-4.64-.932-6.259-2.44m0 0A9.094 9.094 0 0 1 6 11.25c0-2.436.932-4.64 2.44-6.259m0 0A9.094 9.094 0 0 1 12 2.25c2.436 0 4.64.932 6.259 2.44m-6.259 2.44A9.094 9.094 0 0 1 18 11.25c0 2.436-.932 4.64-2.44 6.259" />
                    </svg>
                    <h4>Population &amp; Aim</h4>
                    <p><strong>Population:</strong> N=40 R/R DLBCL<br><strong>Aim:</strong> To find the RP2D and assess safety/efficacy of ZV + R-GemOx.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg style="color: var(--sobi-teal);" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor">
                        <path stroke-linecap="round" stroke-linejoin="round" d="M10.5 6h9.75M10.5 6a1.5 1.5 0 1 1-3 0m3 0a1.5 1.5 0 1 0-3 0M3.75 6H7.5m3 12h9.75m-9.75 0a1.5 1.5 0 0 1-3 0m3 0a1.5 1.5 0 0 0-3 0m-3.75 0H7.5m9-6h3.75m-3.75 0a1.5 1.5 0 0 1-3 0m3 0a1.5 1.5 0 0 0-3 0m-9.75 0h9.75" />
                    </svg>
                    <h4>Intervention</h4>
                    <p>Zilovertamab Vedotin (ZV) + R-GemOx. <strong>RP2D: ZV 1.75 mg/kg</strong></p>
                </div>
                <div class="visual-abstract-item">
                     <svg style="color: var(--sobi-orange);" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor">
                        <path stroke-linecap="round" stroke-linejoin="round" d="M3 13.125C3 12.504 3.504 12 4.125 12h2.25c.621 0 1.125.504 1.125 1.125v6.75C7.5 20.496 6.996 21 6.375 21h-2.25A1.125 1.125 0 0 1 3 19.875v-6.75ZM9.75 8.625c0-.621.504-1.125 1.125-1.125h2.25c.621 0 1.125.504 1.125 1.125v11.25c0 .621-.504 1.125-1.125 1.125h-2.25a1.125 1.125 0 0 1-1.125-1.125V8.625ZM16.5 4.125c0-.621.504-1.125 1.125-1.125h2.25C20.496 3 21 3.504 21 4.125v15.75c0 .621-.504 1.125-1.125 1.125h-2.25a1.125 1.125 0 0 1-1.125-1.125V4.125Z" />
                    </svg>
                    <h4>Key Efficacy Result (at RP2D)</h4>
                    <p>At the 1.75 mg/kg dose:</p>
                    <span class="highlight-value">ORR: 56%</span>
                    <p>Complete Response Rate: 50%</p>
                </div>
                <div class="visual-abstract-item">
                     <svg style="color: var(--sobi-dark-blue);" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor">
                         <path stroke-linecap="round" stroke-linejoin="round" d="M9 12.75 11.25 15 15 9.75M21 12a9 9 0 1 1-18 0 9 9 0 0 1 18 0Z" />
                    </svg>
                    <h4>Key Conclusion</h4>
                    <p><strong>Safety:</strong> Manageable safety profile.<br><strong>Conclusion:</strong> Promising activity, supporting the ongoing Phase 3 evaluation.</p>
                </div>
            </div>
        </div>
        
        <header>
            <h1 class="abstract-header-title">PS1924: Zilovertamab vedotin plus standard of care in relapsed or refractory diffuse large b-cell lymphoma: Results from the phase 2/3 waveLINE-003 study</h1>
            <p class="abstract-sub-header">P. Armand, S. T. Lee, W. Jurczak, D. Stevens, S. Choquet, H. Ghesquieres, et al.</p>
            <p class="abstract-meta-info">Presented at the European Hematology Association (EHA) Congress 2025</p>
        </header>

        <main>
            <div class="abstract-card">
                <h2 class="abstract-section-title">Background</h2>
                <ul class="list-disc">
                    <li>The receptor tyrosine kinase-like orphan receptor 1 (ROR-1) is a cell-surface protein overexpressed in various lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). </li>
                    <li>Zilovertamab vedotin (ZV) is a novel antibody-drug conjugate (ADC) that targets ROR-1 and delivers a monomethyl auristatin E (MMAE) payload. A previous phase 2 study in relapsed or refractory (R/R) DLBCL showed an objective response rate (ORR) of 29%. </li>
                    <li>Rituximab plus gemcitabine and oxaliplatin (R-GemOx) is a commonly used second-line treatment for patients with DLBCL who are not eligible for autologous stem cell transplantation (ASCT). </li>
                    <li>Given their different mechanisms of action, combining ZV with R-GemOx may offer synergistic benefits for treating R/R DLBCL. </li>
                </ul>
            </div>

            <div class="abstract-card">
                <h2 class="abstract-section-title">Aims</h2>
                <p>To present the results from the phase 2 dose confirmation stage of the waveLINE-003 study, evaluating the safety and efficacy of ZV combined with R-GemOx in patients with R/R DLBCL. </p>
            </div>

            <div class="abstract-card">
                <h2 class="abstract-section-title">Methods & Study Design</h2>
                <ul class="list-disc">
                    <li>This analysis is from the phase 2 portion of the waveLINE-003 study (NCT05139017), a phase 2/3 trial. </li>
                    <li><strong>Participants:</strong> Patients with R/R DLBCL.</li>
                    <li><strong>Study Design:</strong> The phase 2 portion was a dose confirmation study to establish the recommended phase 2 dose (RP2D). It evaluated three dose levels of ZV (1.5, 1.75, and 2.0 mg/kg) in combination with standard R-GemOx. </li>
                    <li><strong>Endpoints:</strong>
                        <ul class="list-circle">
                           <li>Primary endpoints were safety and determination of the RP2D. </li>
                           <li>Tertiary and exploratory endpoints included ORR, duration of response (DOR), and overall survival (OS), assessed by BICR per Lugano 2014 criteria. </li>
                        </ul>
                    </li>
                     <li><strong>Data Cut-off:</strong> August 1, 2024. </li>
                </ul>
                <div class="study-design-schema">
                    <div class="schema-title">waveLINE-003 Phase 2 Study Schema</div>
                    <div class="schema-phases">
                        <div class="schema-phase-group">
                             <div class="schema-enrollment"><strong>Enrollment</strong><br><span>R/R DLBCL Patients</span></div>
                             <div class="schema-arrow">→</div>
                             <div class="schema-phase"><strong>Dose Confirmation Cohorts</strong><span>Patients received ZV + R-GemOx at one of three dose levels:</span>
                                <div>• ZV 1.5 mg/kg (n=17)</div>
                                <div>• ZV 1.75 mg/kg (n=16)</div>
                                <div>• ZV 2.0 mg/kg (n=7)</div>
                             </div>
                             <div class="schema-arrow">→</div>
                             <div class="schema-phase"><strong>Primary Endpoint Assessment</strong><span>Safety & Establishment of RP2D</span>
                                 <div class="schema-assessment-points"><span>Response assessments every 12 weeks</span></div>
                             </div>
                        </div>
                    </div>
                </div>
            </div>

            <h2 class="abstract-section-title">Results</h2>

            <div class="abstract-card">
                <h3 class="abstract-sub-section-title">Patient Characteristics</h3>
                <div class="table-container">
                    <table>
                        <thead>
                            <tr>
                                <th>Characteristic</th>
                                <th>ZV 1.5 mg/kg (n=17)</th>
                                <th>ZV 1.75 mg/kg (n=16)</th>
                                <th>ZV 2.0 mg/kg (n=7)</th>
                                <th>Total (N=40)</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr><td><strong>Median Age (range), years</strong></td><td>62.0 (27-78)</td><td>68.5 (32-78)</td><td>59.0 (42-81)</td><td>66.5 (27-81)</td></tr>
                            <tr><td><strong>Age &ge;65 years, n (%)</strong></td><td>7 (41)</td><td>13 (81)</td><td>2 (29)</td><td>22 (55)</td></tr>
                            <tr><td><strong>ECOG PS 0 / 1, n (%)</strong></td><td>8 (47) / 8 (47)</td><td>4 (25) / 10 (63)</td><td>4 (57) / 2 (29)</td><td>17 (43) / 21 (53)</td></tr>
                            <tr><td><strong>Ann Arbor Stage III / IV, n (%)</strong></td><td>6 (35) / 9 (53)</td><td>3 (19) / 8 (50)</td><td>1 (14) / 4 (57)</td><td>8 (20) / 21 (53)</td></tr>
                            <tr><td><strong>Median Prior Lines (range)</strong></td><td>2.0 (1-7)</td><td>2.0 (1-7)</td><td>2.0 (1-3)</td><td>2.0 (1-7)</td></tr>
                             <tr><td><strong>DLBCL Cell of Origin, GCB / non-GCB, n (%)</strong></td><td>5 (29) / 8 (47)</td><td>9 (56) / 5 (31)</td><td>4 (57) / 2 (29)</td><td>18 (45) / 15 (38)</td></tr>
                        </tbody>
                    </table>
                    <div class="footnote-text"><p>Data sourced from Table 1 of the poster.  Percentages may not sum to 100 due to rounding or missing data.</p></div>
                </div>
            </div>
            
            <div class="abstract-card">
                <h3 class="abstract-sub-section-title">Safety</h3>
                <ul>
                   <li>The recommended phase 2 dose (RP2D) was determined to be <strong>ZV 1.75 mg/kg</strong> plus R-GemOx. </li>
                   <li>The combination showed a manageable safety profile. </li>
                   <li>A total of 7 dose-limiting toxicities (DLTs) occurred across all cohorts. </li>
                </ul>
                <div class="table-container">
                    <table>
                        <thead>
                            <tr>
                                <th>Adverse Event Summary, n (%)</th>
                                <th>ZV 1.5 mg/kg (n=17)</th>
                                <th>ZV 1.75 mg/kg (n=16)</th>
                                <th>ZV 2.0 mg/kg (n=7)</th>
                                <th>Total (N=40)</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr><td><strong>Any Drug-Related AE</strong></td><td>16 (94)</td><td>16 (100)</td><td>7 (100)</td><td>39 (98)</td></tr>
                            <tr><td><strong>Grade 3 or 4 Drug-Related AE</strong></td><td>9 (53)</td><td>10 (63)</td><td>6 (86)</td><td>25 (63)</td></tr>
                            <tr><td><strong>Serious Drug-Related AE</strong></td><td>4 (24)</td><td>5 (31)</td><td>4 (57)</td><td>13 (33)</td></tr>
                            <tr><td><strong>AE Leading to Discontinuation</strong></td><td>0 (0)</td><td>0 (0)</td><td>2 (29)</td><td>2 (5)</td></tr>
                            <tr><td><strong>AE Leading to Death</strong></td><td>0 (0)</td><td>0 (0)</td><td>1 (14)</td><td>1 (3)</td></tr>
                        </tbody>
                    </table>
                     <div class="footnote-text"><p>Data sourced from Table 2 of the poster. </p></div>
                </div>
            </div>
            
            <div class="abstract-card">
                 <h3 class="abstract-sub-section-title">Efficacy</h3>
                 <p>At the RP2D of 1.75 mg/kg, the ORR was 56% and the Complete Response (CR) rate was 50%.  The overall CR rate for the total population was 45%. </p>
                 
                <h4 class="abstract-sub-section-title">Complete Response Rate (CRR) by Cohort</h4>
                <div class="chart-container" id="crr-chart-container"></div>
                <div class="legend" id="crr-chart-legend">
                    <div class="legend-item"><span class="legend-color-box" style="background-color: var(--sobi-teal);"></span>Complete Response (CR)</div>
                </div>
                <div class="footnote-text"><p>Chart based on data from Table 3 of the poster.  CRR is shown as the percentage of patients achieving a complete response.</p></div>

                <h4 class="abstract-sub-section-title">Best Objective Response (Overall Population, N=40)</h4>
                 <div class="table-container">
                     <table>
                         <thead>
                             <tr>
                                 <th>Response</th>
                                 <th>ZV 1.5 mg/kg (n=17)</th>
                                 <th>ZV 1.75 mg/kg (n=16)</th>
                                 <th>ZV 2.0 mg/kg (n=7)</th>
                                 <th>Total (N=40)</th>
                             </tr>
                         </thead>
                         <tbody>
                             <tr><td><strong>Complete Response Rate (CRR), % (95% CI)</strong></td>
                                 <td>24 (7-52)</td>
                                 <td>56 (30-80)</td>
                                 <td>57 (18-90)</td>
                                 <td>45 (29-62)</td>
                             </tr>
                             <tr><td><strong>Complete Response (CR), n (%)</strong></td>
                                 <td>4 (24)</td>
                                 <td>9 (56)</td>
                                 <td>4 (57)</td>
                                 <td>18 (45)</td>
                             </tr>
                         </tbody>
                     </table>
                     <div class="footnote-text"><p>Data from Table 3 of the poster.  Partial Response data was not included in the table.</p></div>
                 </div>

                <h4 class="abstract-sub-section-title">Duration of Response (DOR) and Overall Survival (OS)</h4>
                <p>Median DOR and OS were not reached in the RP2D cohort at the time of data cut-off. </p>
                <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-top: 15px;">
                    <div class="km-plot-container zoomable-image-container">
                        <img src="../images/Armand_EHA2025_PS1924_Fig5_DOR.png" alt="Kaplan-Meier estimates of DOR" class="zoomable-image">
                        <p class="footnote-text" style="text-align: center;">Figure 5: Kaplan-Meier estimates of DOR </p>
                    </div>
                    <div class="km-plot-container zoomable-image-container">
                        <img src="../images/Armand_EHA2025_PS1924_Fig6_OS.png" alt="Kaplan-Meier estimates of OS" class="zoomable-image">
                        <p class="footnote-text" style="text-align: center;">Figure 6: Kaplan-Meier estimates of OS</p>
                    </div>
                </div>
            </div>
            
            <div class="abstract-card">
                <h2 class="abstract-section-title">Summary & Conclusion</h2>
                <ul class="list-disc">
                    <li>In the dose confirmation phase of waveLINE-003, the RP2D of ZV in combination with R-GemOx was determined to be 1.75 mg/kg. </li>
                    <li>The combination demonstrated a manageable safety profile. </li>
                    <li>At the RP2D, the ORR of 56% and CR rate of 50% suggest improved clinical activity compared to historical data for R-GemOx alone in R/R DLBCL. </li>
                    <li>The phase 3 portion of the study, randomizing patients to ZV plus R-GemOx versus R-GemOx alone, is currently enrolling. </li>
                    <li>ZV is also being evaluated in first-line DLBCL settings in other trials (waveLINE-010 and waveLINE-011). </li>
                </ul>
            </div>
            
            <div class="abstract-card">
                <h2 class="abstract-section-title">Reference
                    <button id="copyReferenceBtn" class="copy-reference-button">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M7 3.5A1.5 1.5 0 0 1 8.5 2h3.879a1.5 1.5 0 0 1 1.06.44l3.122 3.12A1.5 1.5 0 0 1 17 6.622V16.5a1.5 1.5 0 0 1-1.5 1.5h-8A1.5 1.5 0 0 1 6 16.5v-13A1.5 1.5 0 0 1 7 3.5Zm1.5 0h3.879a.5.5 0 0 1 .353.146L16.354 7.27a.5.5 0 0 1-.353.854H11.5A1.5 1.5 0 0 1 10 6.622V2.5A1.5 1.5 0 0 1 8.5 5V3.5Z" /><path d="M4 7a.5.5 0 0 1 .5.5v10a.5.5 0 0 0 .5.5h8a.5.5 0 0 0 .5-.5v-2.5a.75.75 0 0 1 1.5 0V17.5a2 2 0 0 1-2 2h-8a2 2 0 0 1-2-2V7.5A.5.5 0 0 1 4 7Z" /></svg>
                        Copy
                    </button>
                </h2>
                <p id="referenceSectionContent">Armand P, Lee ST, Jurczak W, et al. Zilovertamab vedotin plus standard of care in relapsed or refractory diffuse large b-cell lymphoma: Results from the phase 2/3 waveLINE-003 study. Abstract #PS1924 presented at the European Hematology Association (EHA) Congress. 12–15 June 2025, Milan, Italy.</p>
            </div>
            
             <footer class="abstract-footer-info">
                <p>Trial Identifier: NCT05139017  | Data Cut-off: August 1, 2024  | Poster available via QR code on original document </p>
            </footer>
        </main>
    </div>

    <script>
        document.addEventListener('DOMContentLoaded', function () {
            // D3.js Chart for CRR
            const crrData = [
                { cohort: "ZV 1.5 mg/kg", value: 24 },
                { cohort: "ZV 1.75 mg/kg (RP2D)", value: 56 },
                { cohort: "ZV 2.0 mg/kg", value: 57 },
                { cohort: "Total", value: 45 }
            ];

            const container = document.getElementById('crr-chart-container');
            const margin = { top: 20, right: 20, bottom: 60, left: 40 },
                width = container.clientWidth - margin.left - margin.right,
                height = 350 - margin.top - margin.bottom;

            const svg = d3.select("#crr-chart-container").append("svg")
                .attr("width", width + margin.left + margin.right)
                .attr("height", height + margin.top + margin.bottom)
                .append("g")
                .attr("transform", `translate(${margin.left},${margin.top})`);

            const x = d3.scaleBand()
                .range([0, width])
                .domain(crrData.map(d => d.cohort))
                .padding(0.4);

            svg.append("g")
                .attr("transform", `translate(0, ${height})`)
                .call(d3.axisBottom(x))
                .selectAll("text")
                .attr("transform", "translate(-10,0)rotate(-45)")
                .style("text-anchor", "end")
                .attr("class", "axis-text");

            const y = d3.scaleLinear()
                .domain([0, 100])
                .range([height, 0]);

            svg.append("g")
                .call(d3.axisLeft(y).ticks(5).tickFormat(d => d + "%"))
                .attr("class", "axis-text");

            svg.selectAll("mybar")
                .data(crrData)
                .enter()
                .append("rect")
                .attr("x", d => x(d.cohort))
                .attr("y", d => y(d.value))
                .attr("width", x.bandwidth())
                .attr("height", d => height - y(d.value))
                .attr("fill", "var(--sobi-teal)");
            
            svg.selectAll(".bar-label")
                .data(crrData)
                .enter()
                .append("text")
                .attr("class", "chart-label")
                .attr("x", d => x(d.cohort) + x.bandwidth() / 2)
                .attr("y", d => y(d.value) - 5)
                .attr("text-anchor", "middle")
                .text(d => d.value + "%");
        });
    </script>
</body>
</html>